Novalgine I.M./I.V. (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which decreases the production of prostaglandins that sensitize nerve endings and raise body temperature. It may also modulate endogenous opioid pathways, enhancing analgesic effects without directly activating opioid receptors.

The specific dose of Novalgine I.M./I.V. is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and response to therapy. Healthcare professionals follow local guidelines and adjust the regimen as needed.

Safety data for metamizole in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with traditional NSAIDs, metamizole offers potent analgesic and antipyretic effects with a lower incidence of gastrointestinal irritation but carries a unique risk of agranulocytosis. Selection depends on the clinical scenario, patient risk factors, and the therapeutic profile required by the prescriber.

Novalgine I.M./I.V. should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect from moisture and light. The solution must be inspected for particulate matter before administration and used within the expiry date.

The product is supplied as a sterile injectable solution for intramuscular or intravenous injection. Administration is performed by qualified healthcare personnel using aseptic technique, with dosage and rate of infusion determined by the treating physician.

The most serious risks include agranulocytosis, which can lead to severe infections, and rare hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Prompt monitoring of blood counts and immediate medical attention for any signs of severe allergic reaction are essential.

Novalgine I.M./I.V. is contraindicated in patients with known hypersensitivity to metamizole or other pyrazolones, in individuals with a history of agranulocytosis, and in those with severe hepatic or renal impairment where the risk outweighs benefit. Clinical judgment is required for all other cases.